2025 Fall Clinical Dermatology Conference

Fifty-four percent of patients ages 12 to 18 with severe alopecia noticed hair regrowth when given 4-mg of Olumiant (oral baricitinib), according to results of a study presented this week at the 2025 Fall Clinical Dermatology conference.

In this second segment of an interview with Managed Healthcare Executive about this presentation about aesthetic dermatology at the 2025 Fall Clinical Dermatology Conference, Mark S.Nestor, M.D., Ph.D., discussed botulinum toxin injections, the effects that injections into the glalbella can have on depression and differing molecular potencies of the different brands of botulinum toxin.

In this first segment from an interview with Managed Healthcare Executive about his presentation about trends in aesthetic dermatology, the 2025 Fall Clinical Dermatology Conference in Las Vegas, Mark S. Nestor, M.D., Ph.D., talks about the shift away from hyaluronic acid to collagen stimulators, such as poly-L-lactic acid.

Benjamin Lockshin, M.D., from Georgetown University, discusses how oral TYK2 inhibitors that rival biologics’ efficacy have changed the management of patients with psoriasis.

Mona Shahriari, M.D., dermatologist at Central Connecticut Dermatology and an associate clinical professor at Yale School of Medicine discusses the highlights of her session called ‘Seeing Clearly: A Visual Guide to Diagnosing Prurigo Nodularis in Skin of Color.’

Determining a biologic's duration of use to treat pediatric atopic dermatitis has several factors, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.

Expensive, newer therapies and a lack of pediatric data are roadblocks to advancing treatment for pediatric atopic dermatitis, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.

The interleukin-13 inhibitors are an effective treatment for atopic dermatitis.

Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, gives an overview of his session at the 2025 Fall Clinical Dermatology Conference.

Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, discusses why his clinic has shifted towards earlier atopic dermatitis treatment for patients.

New clinical data demonstrate Zoryve's effectiveness in treating atopic dermatitis, reducing sleep disruptions and maintaining disease control with minimal adverse events across all ages.

Shawn Kwatra, M.D., reveals new OX40 ligand therapies for atopic dermatitis, promising new hope for patients at the Fall Clinical Dermatology meeting.

Results of a similar study conducted in Canada and Europe showed a prevalence of 5%.

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.

Shawn Kwatra addresses the complexities of atopic dermatitis and prurigo nodularis at the Fall Clinical Dermatology Conference, emphasizing tailored treatment strategies.

James Song, M.D., discusses IL-23 inhibitors’ drug persistence in psoriasis treatment, new systemic therapy criteria, and upcoming oral medications that may rival biologics’ efficacy.